CogstateASX:CGS -1.47%77 Net Debt Paydown Yield % is 0.05% as of Jul. 02, 2026, which is 17% below its 10-year median of 0.06. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 623 Healthcare Providers & Services companies, Cogstate ranks better than 56.34% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Cogstate's Net Debt Paydown Yield % was 0.05%.
Cogstate (ASX:CGS) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for Cogstate's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CGS vs VEEV, BTSG, TEM: Net Debt Paydown Yield % Comparison
For the Health Information Services subindustry, Cogstate's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate Net Debt Paydown Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Cogstate's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.05% mean?
Cogstate (ASX:CGS) has a Net Debt Paydown Yield % of 0.05% as of Jul. 02, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Cogstate and its competitors. This is 17% below median its historical median of 0.06. According to the industry distribution chart, Cogstate ranks #272 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 43.7%.
Is Cogstate's Net Debt Paydown Yield % too high?
Cogstate's current Net Debt Paydown Yield % of 0.05% is 17% below median its 10-year median of 0.06. Based on the distribution chart, Cogstate ranks #272 out of 623 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cogstate has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Net Debt Paydown Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #272 out of 623 companies for Net Debt Paydown Yield %. This puts Cogstate in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Healthcare Providers & Services company?
A good Net Debt Paydown Yield % depends on the Healthcare Providers & Services industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Cogstate and its competitors. Cogstate's current Net Debt Paydown Yield % is 0.05%, which is 17% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.06, compared to a current price of A$2.69 — trading 30.6% above its estimated fair value. The current Net Debt Paydown Yield % is 0.05%, which is 17% below median its 10-year median of 0.06. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Net Debt Paydown Yield % is 0.05% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (ASX:CGS) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of A$2.69 is trading 30.6% above its estimated GF Value™ of A$2.06.
GuruFocus considers Cogstate to be Significantly Overvalued.
Key valuation signals for ASX:CGS:
Net Debt Paydown Yield %: 0.05% (17% below median its 10-year median of 0.06)
GF Value™: A$2.06 vs. price of A$2.69 (30.6% above fair value)
No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score
Get the complete analysis for ASX:CGS
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGS has been successfully added to your 
